AMRN

AmarinB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

Curated Events

Active

Recent Headlines

New

Curated events

Materiality

earnings

Source

External coverage

Decided

2026-07-29

Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss

Amarin beat Q4 earnings estimates, but missed on revenue and the stock declined, creating a negative immediate read-through.

View event details

Sentiment decomposition

0.0

30-day score

Company-55%

Macro-30%

Pulse-15%

Weekly research-10-day

Company, Macro, and Pulse form the existing 30-day artifact blend. Weekly research is tracked separately for 10 days and can contribute at most 10% of the sentiment pillar when live mode is enabled.

Recent headlines

Headline

Time

Relevance

Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA/VASCEPA (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer Liver Metastases (CRCLM)

2026-10-25

13%

External coverage

Amarin's Leaner Model Faces A Proof Test As Europe Must Offset US Erosion

2026-10-22

External coverage

Amarin to Report Third Quarter 2026 Financial Results and Host Conference Call on October 28, 2026

2026-10-21

External coverage

Amarin to Present New REDUCE-IT and EPA Analyses at ESC Congress 2026

2026-08-24

13%

External coverage

New Analyses from REDUCE-IT and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026

2026-08-24

13%

External coverage

Amarin Corp PLC (AMRN) Q2 2026 Earnings Call Highlights: Strategic Growth Amidst Revenue Challenges

2026-07-29

13%

External coverage

As of 2026-07-29 • Updated scheduledSource: News desk